Adicet Bio, Inc. (ACET) Valuation — DCF, Graham & Comparables

Adicet Bio, Inc. (ACET) — Price $9.05 HealthcareBiotechnology — NASDAQ

Latest reported results:

Valuation dashboard for Adicet Bio, Inc. (ACET) with P/E N/A, P/B 0.82, EV/EBITDA -0.77 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.

Analysis Summary

Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.

At the current price of $9.05, ACET has negative trailing earnings (P/E not meaningful) and an ROE of -74.90%. Market capitalisation stands at $85M.

Balance sheet quality for ACET: current ratio of 7.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book0.82
EV / EBITDA-0.77
Dividend Yield0.00%

Valuation Models

DCF Fair Value$2.93
vs Current Price-67.6%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
ACETAdicet Bio, Inc.$85M0.82-74.9%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.6B29.766.4623.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$9.05
Market Cap$85M
ExchangeNASDAQ
CountryUS

Profitability

Return on Equity-74.90%
Return on Invested Capital-77.98%
Return on Assets-66.80%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: ACRV · ADAG · CRVO · GANX · HOWL · IMUX · IOBT

Explore sector: Healthcare · Biotechnology

More sections of ACET: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks